Alira Health

Alira Health

Key Considerations for Cell and Gene Therapy Commercialization in Non-Orphan Indications

White Paper

Cell and gene therapies (CGTs) present significant potential across a wide range of diseases including cancer, genetic disorders, and autoimmune conditions. Outside of oncology, CGT development has mainly focused on orphan and ultra-orphan indications.  

Companies currently developing in or planning to enter the CGT space must prepare for the market shift from targeted niche development to this broader pursuit. Commercializing CGTs in non-orphan indications will be fundamentally different than the experience to date.

This white paper will focus on the expansion of CGTs into non-orphan indications outside of oncology. It will examine the viability of developing a CGT in a non-orphan indication and address key considerations when evaluating the business case for a successful CGT product in a mainstream market, including pricing and delivery ecosystem considerations. 

Download Key Considerations for Cell and Gene Therapy Commercialization in Non-Orphan Indications now.

CGT Commercialization in Non-Orphan Indications

Fill out the form to download this white paper. 

 

Welcome to Alira Health. This site is best viewed in Chrome, Microsoft Edge, or Firefox.